|
EASTERN COOPERATIVE ONCOLOGY GROUP
|
3U10CA014958-38S1
|
$144,167
|
$1,442
|
Sparano, Joseph
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Nemours Community Clinical Oncology Program
|
1U10CA176879-01
|
$558,366
|
$33,502
|
SANDLER, ERIC
|
ALFRED I. DU PONT HOSP FOR CHILDREN
|
|
Radiation Therapy Oncology Group
|
5U10CA021661-37
|
$14,566,378
|
$145,664
|
Curran, Walter
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
American College of Radiology Imaging Network
|
3U10CA080098-14S2
|
$5,146,722
|
$51,467
|
Schnall, Mitchell
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
Bay Area Tumor Institute CCOP
|
5U10CA045461-24
|
$486,165
|
$14,585
|
Feusner, James
|
BAY AREA TUMOR INSTITUTE
|
|
Virginia Mason Community Clinical Oncology Program
|
5U10CA035192-29
|
$612,504
|
$6,125
|
Nichols, Craig
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
Mechanism of Acquired Resistance to VEGF-R Antagonists in RCC
|
5K08CA138900-04
|
$169,560
|
$169,560
|
BHATT, RUPAL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Eastern Cooperative Oncology Group
|
3U10CA080775-14S1
|
$43,980
|
$440
|
BUBLEY, GLENN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Targeting the PI3-Kinase/Akt Pathway for the Therapy of Renal Cell Carcinoma
|
5K08CA142890-05
|
$169,400
|
$169,400
|
Cho, Daniel
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Novel treatment strategies for enhancing sunitinib response in renal cell cancer
|
1R21CA176912-01
|
$227,070
|
$227,070
|
LIBERMANN, TOWIA
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
DF/HCC Kidney Cancer SPORE
|
5P50CA101942-10
|
$2,150,502
|
$2,150,502
|
McDermott, David
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Pathway Specific Imaging in VHL Deficient Renal Cancer
|
5R01CA152330-03
|
$334,047
|
$334,047
|
SETH, PANKAJ
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
The pVHL/Jade-1/beta-catenin axis in renal cancer
|
3R01CA079830-12S1
|
$64,824
|
$64,824
|
COHEN, HERBERT
|
BOSTON MEDICAL CENTER
|
|
The pVHL/Jade-1/beta-catenin axis in renal cancer
|
5R01CA079830-12
|
$300,984
|
$300,984
|
COHEN, HERBERT
|
BOSTON MEDICAL CENTER
|
|
VHL tumor suppressor gene and the initiation of renal cell carcinoma
|
3R01CA109860-09S1
|
$88,962
|
$88,962
|
HSU, TIEN
|
BOSTON MEDICAL CENTER
|
|
VHL tumor suppressor gene and the initiation of renal cell carcinoma
|
5R01CA109860-09
|
$308,789
|
$308,789
|
HSU, TIEN
|
BOSTON MEDICAL CENTER
|
|
The MB-CCOP at Boston Medical Center
|
3U10CA139519-03S3
|
$501,282
|
$5,013
|
Kachnic, Lisa
|
BOSTON MEDICAL CENTER
|
|
The MB-CCOP at Boston Medical Center
|
3U10CA139519-03S4
|
$122,789
|
$1,228
|
Kachnic, Lisa
|
BOSTON MEDICAL CENTER
|
|
Cancer and Leukemia Group B CCOP Research Base
|
3U10CA037447-28S1
|
$362,418
|
$14,497
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Cancer and Leukemia Group B
|
5U10CA031946-32
|
$9,816,255
|
$785,300
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Cancer and Leukemia Group B CCOP Research Base
|
5U10CA037447-29
|
$2,684,982
|
$107,399
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Molecular Pathogenesis of the Hamartoma Syndromes
|
5P01CA120964-07
|
$1,672,978
|
$133,838
|
KWIATKOWSKI, DAVID
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Computerized Monitoring Tool for MR-Guided Cryoablation
|
5R01CA152282-04
|
$417,353
|
$417,353
|
Tuncali, Kemal
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Proteo-genomic Discovery, Prioritization and Verification of Cancer Biomarkers
|
5U24CA160034-03
|
$3,019,843
|
$754,961
|
CARR, STEVEN
|
BROAD INSTITUTE, INC.
|
|
Biostatistics Data Management Center for ACRIN
|
3U10CA079778-14S1
|
$2,271,308
|
$22,713
|
Gatsonis, Constantine
|
BROWN UNIVERSITY
|
|
Engineering Triggered Nanomechanical Therapeutics
|
5R01CA140759-05
|
$303,525
|
$106,234
|
PIERCE, NILES
|
CALIFORNIA INSTITUTE OF TECHNOLOGY
|
|
Eastern Cooperative Oncology Group Studies
|
3U10CA014548-38S1
|
$334,918
|
$3,349
|
AVERBOOK, BRUCE
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
2P30CA043703-23
|
$4,740,480
|
$94,810
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-23S2
|
$37,026
|
$741
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Staging of upper tract urothelial cancer with optical coherence tomography
|
5R21CA165398-02
|
$244,983
|
$244,983
|
ROLLINS, ANDREW
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Expression profiling of renal cell carcinoma utilizing tissue from CALGB 90206
|
5R01CA133072-07
|
$353,636
|
$353,636
|
KIM, HYUNG
|
CEDARS-SINAI MEDICAL CENTER
|
|
Children's Oncology Group Chair's Grant
|
5U10CA098543-11
|
$24,894,951
|
$2,987,394
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Community Clinical Oncology Program Research Base
|
5U10CA095861-12
|
$1,884,051
|
$226,086
|
POLLOCK, BRAD
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Cadherin-regulated apoptosis and survival signaling in epithelial cells
|
5R01CA142647-03
|
$339,387
|
$339,387
|
HANSEN, STEEN
|
CHILDREN'S HOSPITAL CORPORATION
|
|
Novel Therapeutic Targets For Calcineurin Inhibitor-Induced And mTOR-Mediated Can
|
1R21CA172946-01A1
|
$228,375
|
$228,375
|
Pal, Soumitro
|
CHILDREN'S HOSPITAL CORPORATION
|
|
Pathophysiology of Post-Transplantation Cancer
|
5R01CA131145-05
|
$329,206
|
$329,206
|
Pal, Soumitro
|
CHILDREN'S HOSPITAL CORPORATION
|
|
Delaware/Christiana Care Community Clinical Oncology Program
|
5U10CA045418-27
|
$1,543,934
|
$30,879
|
Grubbs, Stephen
|
CHRISTIANA CARE HEALTH SERVICES, INC.
|
|
City of Hope Southwest Oncology Group Clinical Trials
|
5U10CA046368-26
|
$340,319
|
$30,629
|
MORTIMER, JOANNE
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Regulation of MDSC function and trafficking
|
1R01CA168488-01A1
|
$375,343
|
$187,672
|
FINKE, JAMES
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Sunitinib Modulation of Cancer Immunotherapy
|
5R01CA150959-04
|
$491,332
|
$491,332
|
FINKE, JAMES
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Germline KLLN Alterations in PTEN Mutation Negative Cowden Syndrome
|
1F30CA168151-01A1
|
$34,580
|
$17,290
|
PONTZER, EMILY
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Columbia University Medical Center Minority-Based Community Clinical Oncology Pro
|
5U10CA167791-02
|
$796,302
|
$31,852
|
KELLY, KARA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Columbus Community Clinical Oncology Program (Columbus CCOP)
|
5U10CA035261-30
|
$733,151
|
$7,332
|
KUEBLER, J
|
COLUMBUS COMMUNITY CLINICAL ONCOLOGY PRG
|
|
Cancer Center Support Grant
|
3P30CA006516-48S1
|
$114,538
|
$1,145
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
3P30CA006516-48S3
|
$12,500
|
$125
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
3P30CA006516-48S4
|
$50,000
|
$500
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
5P30CA006516-48
|
$10,435,722
|
$104,357
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer and Leukemia Group B
|
5U10CA032291-32
|
$454,439
|
$36,355
|
Burstein, Harold
|
DANA-FARBER CANCER INST
|
|
ECOG Statistical Office
|
5U10CA023318-37
|
$1,894,415
|
$18,944
|
GRAY, ROBERT
|
DANA-FARBER CANCER INST
|
|
The von Hippel-Lindau Tumor Suppressor Protein:Roles in Cancer and Oxygen Sensing
|
5R01CA068490-18
|
$274,747
|
$274,747
|
KAELIN, WILLIAM
|
DANA-FARBER CANCER INST
|
Total relevant funding to Kidney Cancer for this search: $45,589,825
|